Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)

BMC Psychiatry

Study Protocol

Joo-Cheol Shim¹  Robert P McMahon²  Dale Warfel²  Amber K Earl²  William R Keller²  Heidi J Wehring²  Stephanie Feldman²  Deanna L Kelly²  Robert W Buchanan²  Kelli M Sullivan²  Bernard A Fischer³  Faith B Dickerson⁴ 

[1] Department of Psychiatry and Clinical Trial Center, Busan Paik Hospital, Inje University, Busan, South Korea;School of Medicine, Maryland Psychiatric Research Center, University of Maryland Baltimore, Baltimore, Maryland, USA;School of Medicine, Maryland Psychiatric Research Center, University of Maryland Baltimore, Baltimore, Maryland, USA;VA Capital Network (VISN 5) Mental Illness Research, Education, and Clinical Center (MIRECC), Baltimore, Maryland, USA;Sheppard and Enoch Pratt Hospital, Baltimore, Maryland, USA;

关键词: Women;    Prolactin;    Amenorrhea;    Galactorrhea;    Clinical trial;    Sexual dysfunction;    Osteoporosis;    Aripiprazole;   

DOI  :  10.1186/1471-244X-13-214

 received in 2013-04-18, accepted in 2013-08-07,  发布年份 2013

来源: Springer

【 摘 要 】

Prolactin elevations occur in people treated with antipsychotic medications and are often much higher in women than in men. Hyperprolactinemia is known to cause amenorrhea, oligomenorrhea, galactorrhea and gynecomastia in females and is also associated with sexual dysfunction and bone loss. These side effects increase risk of antipsychotic nonadherence and suicide and pose significant problems in the long term management of women with schizophrenia. In this manuscript, we review the literature on prolactin; its physiology, plasma levels, side effects and strategies for treatment. We also present the rationale and protocol for an ongoing clinical trial to treat symptomatic hyperprolactinemia in premenopausal women with schizophrenia. More attention and focus are needed to address these significant side effects and help the field better personalize the treatment of women with schizophrenia.

【 授权许可】

CC BY   
© Kelly et al.; licensee BioMed Central Ltd. 2013